Suvizumab, CAS 914257-21-9

Product Description: Suvizumab (KD-247) is an neutralizing antibody anti-HIV-1. Suvizumab effectively neutralizes HIV-1MN, HIV-1SF2 and HIV-189.6 with IC50 values of 0.1 µg/mL, 1.0 µg/mL and 0.2 µg/mL, respectively. Suvizumab reduces the viral load of HIV. Suvizumab has good tolerance and can be used to prevent HIV infection[1][2].

Applications: COVID-19-anti-virus

Formula: N/A

References: [1]Eda Y, et al. Anti-V3 humanized antibody KD-247 effectively suppresses ex vivo generation of human immunodeficiency virus type 1 and affords sterile protection of monkeys against a heterologous simian/human immunodeficiency virus infection. J Virol. 2006 Jun;80(11):5563-70./[2]Yoshimura K, et al. Resistance profile of a neutralizing anti-HIV monoclonal antibody, KD-247, that shows favourable synergism with anti-CCR5 inhibitors. AIDS. 2006 Oct 24;20(16):2065-73. /[3]Murakami T, et al. Postinfection passive transfer of KD-247 protects against simian/human immunodeficiency virus-induced CD4+ T-cell loss in macaque lymphoid tissue. AIDS. 2009 Jul 31;23(12):1485-94. /[4]Matsushita S, et al. Passive transfer of neutralizing mAb KD-247 reduces plasma viral load in patients chronically infected with HIV-1. AIDS. 2015 Feb 20;29(4):453-62.

CAS Number: 914257-21-9

Molecular Weight: N/A

Research Area: Infection

Solubility: 10 mM in DMSO

Target: HIV

• Artikelnummer: MEXHY-P99584-0
• Hersteller: MedChemExpress
• Hersteller Artikelnummer: HY-P99584-0
• Verpackungseinheit: Get quote
• Mengeneinheit: STK
• Konjugat: Unconjugated